Weight loss drug gets US nod to treat sleep apnea

FDA approves first medication for obstructive sleep apnea, which also promotes weight loss
The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep expert Dr. Wendy Troxel discusses the impact of the new development.
F.D.A. Approves Weight Loss Drug to Treat Obstructive Sleep Apnea
Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration on Friday approved the weight loss drug Zepbound to treat obstructive sleep apnea. It is the first prescription medication approved to treat the common sleep disorder.
FDA approves weight-loss drug Zepbound for obstructive sleep apnea
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.
Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with sleep apnea and obesity, the drugmaker said after the bell Friday.Trials of the Lilly drug found that it helped reduce the number of breathing disruptions in an average night of sleep.
This Weight Loss Drug Could Also Treat Sleep Apnea
If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a good fit.
Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company said. "Too often, obstructive sleep apnea is brushed off as 'just snoring' - but it's far more than that,
FDA approves weight-loss drug to treat sleep apnea
The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency green-lighted Eli Lilly’s Zepbound drug for the use,
FDA approves weight-loss drug Zepbound to treat sleep apnea
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.
FDA approves weight loss drug Zepbound to treat obstructive sleep apnea
The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
Weight loss drug Zepbound gets US FDA nod to treat sleep apnea; India launch expected in 2025
In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known as Tirzepatide, for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.
The Independent21d
Weight loss drug battle heats up as Wegovy beaten in head-to-head trial
A rival drug company is celebrating results claiming its drug helps patients lose more weight than Novo Nordisk ... health issue such as obstructive sleep apnea or heart disease.
UPI21d
In new trial, Zepbound bests Wegovy for weight loss
Wegovy contains semaglutide, the drug also used in Novo ... to be a possible treatment for obstructive sleep apnea. Importantly, McGowan said weight loss isn't the only factor patients have ...
Reuters13d
EU drugs regulator backs Mounjaro's sleep apnea use without fresh approval for Lilly
Lilly is also seeking approval for the drug in sleep apnea patients in the U.S. Lilly ... Approval for use beyond weight-loss could be a shot in the arm for the companies at a time when ...